Novo Nordisk (NVO), the maker of the blockbuster drug Ozempic, is cutting the price of its weight loss drug by more than half ...

which has an easy auto-injector mechanism. “These marketing authorisations constitute significant milestones for Novo Nordisk and the treatment of diabetes. We look forward to making Tresiba and ...

Eli Lilly began offering vials of the two lowest doses of Zepbound, which is typically sold in auto-injector pens, in August. Danish drugmaker Novo Nordisk will also offer home delivery of ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

Novo Nordisk's hopes of heralding a new era of obesity treatment ... as investors' hopes of finding a superior alternative to ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...

Novo Nordisk (NVO) announced updates to the Wegovy savings program, allowing all eligible cash-paying patients access to Wegovy injection 0.25 ...

Novo Nordisk said on Wednesday it would begin ... which is typically sold in auto-injector pens, in August. It now sells ...

Novo Nordisk, which has led the obesity drug market with its pioneering weight-loss injection Wegovy, in February forecast sales growth in local currencies between 16% and 24% in 2025. Investors ...